Company news

HLS Therapeutics, Inc. news in 2023

HLS Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

HLS Therapeutics Announces CFO Departure

December 18, 2023

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

November 14, 2023

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

November 9, 2023

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

October 26, 2023

HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference

September 6, 2023

HLS Therapeutics Announces Updates to its Credit Agreement

August 14, 2023

HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results

August 10, 2023

HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call

August 3, 2023

HLS Therapeutics Announces Updates to its Board of Directors

June 22, 2023

HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of Directors

June 8, 2023

HLS Therapeutics Announces Q1 Fiscal 2023 Financial Results

May 11, 2023

HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call

May 3, 2023

HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

April 21, 2023

HLS Therapeutics Announces CEO Transition

April 17, 2023

HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results

March 16, 2023

HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference Call

March 2, 2023

Decks in 2023